Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized double-blind placebo-controlled study of efinopegdutide in adults with compensated cirrhosis due to MASH
MOH_2024-06-03_013414Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- May 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of efinopegdutide in metabolic dysfunction-associated steatohepatitis (MASH) and Cirrhosis, sponsored by Merck & Co. Primary endpoint: Relative reduction in liver fat from baseline. Started May 2024; status: recruiting.
02
Drugs
efinopegdutide
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)Cirrhosis
Beyond the preview
Go deeper on MOH_2024-06-03_013414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-06-03_013414.